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Epithelial cells do not generate 
myofibroblasts in kidney fibrosis
Humphreys et al., Am J Pathol advance online publication, 11 December 2009, 
doi:10.2353/ajpath.2010.090517
Most chronic kidney diseases are characterized by replacement of 
the parenchyma by fibrotic tissue, which results from myofibroblast 
proliferation and collagen deposition. Myofibroblasts are contractile 
cells originally described in liver fibrosis and postulated to derive 
from specialized perivascular cells known as hepatic stellate cells. 
A substantial body of work suggests that, following kidney injury, 
epithelial cells undergo a phenotypic transition in which they 
transdifferentiate into interstitial myofibroblasts by a process termed 
epithelial-to-mesenchymal transition. However, other studies sug-
gest that myofibroblasts may derive from perivascular fibroblasts or 
even from endothelial cells or bone marrow-derived cells. Further, it 
was recently found that the media of blood vessels contain mesen-
chymal stem cells, a cell type long known to differentiate, at least in 
vitro, into myofibroblast-like cells. It is obvious that understanding 
the origin and differentiation pathways of renal myofibroblasts in 
vivo is critical for the identification of new therapeutic strategies for 
fibrosing kidney diseases. In an exciting new study, Humphreys et 
al. performed lineage analysis of the different renal cell compart-
ments during fibrogenesis in vivo. They used transgenic or knock-in 
mice with lineage-restricted expression of bacterial Cre recombi-
nase and reporter mice to genetically track three cell populations. 
To label the cells derived from the ureteric bud, they used HoxB7-
Cre mice; to label all non-ureteric-bud-derived nephron epithelia, 
including podocytes, proximal tubule, loop of Henle, and connect-
ing segment, they used the Six2-Cre transgenic mouse. Finally, to 
label the renal interstitial cell population, they used the FoxD1-Cre 
knock-in mouse, as FoxD1 is a well-characterized marker of renal 
stromal cells but not epithelia. Confirming previous observations, 
genetically labeled primary proximal epithelial cells cultured in vitro 
readily developed markers of myofibroblasts upon treatment with 
transforming growth factor-β1. However, during development of 
renal fibrosis by unilateral ureteral obstruction and using different 
cell-fate markers, the authors found no evidence that epithelial cells 
migrated outside the tubular basement membrane and differentiated 
into interstitial myofibroblasts in vivo. In contrast, lineage analysis 
showed that during nephrogenesis, FoxD1-positive mesenchymal 
cells gave rise to adult CD73-positive, platelet-derived growth fac-
tor receptor-β-positive, smooth muscle actin-negative interstitial 
pericytes (Figure), and that these FoxD1-derivative interstitial cells 
expanded and differentiated into smooth muscle actin-positive 
myofibroblasts during fibrosis and accounted for a large majority 
of the myofibroblasts.
Thus, the study provides lineage-tracing evidence that kidney 
epithelial cells do not become myofibroblasts in vivo, but rather 
that interstitial pericytes are myofibroblast progenitors in fibrotic 
kidney disease. These results have important implications for the 
understanding and therapy of renal fibrogenesis.
Qais Al-Awqati
Donor activation of HIFs  
ameliorates graft injury  
in allogenic kidney transplant
Bernhardt et al., Proc Natl Acad Sci USA 2009; 106: 21276–21281; doi:10.1073/
pnas.0903978106
Chronic allograft failure of transplanted kidneys is likely due to 
multiple causes of both immune and nonimmune pathogenesis. It 
is known that acute kidney injury immediately after transplanta-
tion, due to ischemia and reperfusion, impairs early graft function. 
However, acute kidney injury is also associated with reduced long-
term graft survival. Although the causality of this association has 
not been established, it is likely that minimizing early graft injury 
would improve long-term outcome. Many approaches have been 
taken to reduce early graft dysfunction, including optimization of 
the perfusion fluid as well as the use of agents that inhibit some step 
in the pathogenesis of ischemia–reperfusion injury. Bernhardt et 
al. postulated that an effective way to improve early, and possibly 
late, kidney graft function would be to induce the endogenous pro-
tective mechanisms that are activated during kidney injury; they 
specifically investigated whether induction of hypoxia-responsive 
genes could confer protection. Much has recently been learned of 
hypoxia-responsive genes, particularly genes downstream from the 
hypoxia-inducible transcription factors (HIFs). To date, far more 
than 100 HIF target genes have been identified, including eryth-
ropoietin, vascular endothelial growth factor, glucose transporters, 
and heme oxygenase-1, many of which have the potential to confer 
nephroprotection. HIFs are heterodimers of a constitutive β-subunit 
and one of two alternative oxygen-regulated α-subunits, HIF-1α 
and HIF-2α. Under normoxia, HIF-α is rapidly degraded via the 
ubiquitin–proteasome pathway. To target HIF-α for degradation, 
Metanephric mesenchyme-derived interstitial pericytes in the adult 
kidney of FoxD1-GCE;R26R mice; LacZ-expressing cells in the normal 
kidney of FoxD1-GCE;R26R mice. Note that positive cells (arrowheads) are 
exclusively in the interstitium and express the markers CD73 and Pdgfrβ 
but do not express αSma.
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two specific prolyl residues are hydroxylated by HIF-prolyl hydrox-
ylases (prolyl hydroxylation domain (PHD) proteins) that require 
dioxygen and 2-oxoglutarate as co-substrates. Thus, oxoglutarate 
analogs act as competitive inhibitors of PHDs and HIF stabilizers. 
In a rat model of allogenic kidney transplantation, Bernhardt et al. 
found that donor treatment with a specific PHD inhibitor (FG-4497) 
resulted in HIF accumulation and induction of HIF target genes, 
which persisted beyond cold storage. More interestingly, 10 days 
after transplantation, treatment resulted in better renal function 
and preservation of morphology and reduced mortality. Moreover, 
treatment also improved survival of recipient animals at 24 weeks. 
Thus, pretreatment of organ donors with the HIF stabilizer FG-4497 
improved short- and long-term kidney outcomes after allogenic kid-
ney transplantation.
Juan Oliver
A trial of darbepoetin alfa in type 2 
diabetes and chronic kidney disease
Pfeffer et al., N Engl J Med 2009; 361: 2019–2032; doi:10.1056/NEJMoa0907845
The Trial to Reduce Cardiovascular Events with Aranesp Ther-
apy (TREAT), a large international, randomized, double-blind, 
placebo-controlled clinical trial, involves 4038 patients with dia-
betes, chronic kidney disease, and anemia. Two thousand twelve 
patients were randomly assigned to darbepoetin alfa to achieve a 
hemoglobin level of approximately 13 g/dl. The rest of the patients 
were assigned to placebo, with rescue darbepoetin alfa when the 
hemoglobin level was less than 9.0 g/dl. The primary end points 
were the composite outcomes of death or a cardiovascular event 
(nonfatal myocardial infarction, congestive heart failure, stroke, 
or hospitalization for myocardial ischemia) and of death or end-
stage renal disease. The use of darbepoetin alfa in patients with 
diabetes, chronic kidney disease, and moderate anemia who were 
not undergoing dialysis did not reduce the risk of either of the 
two primary composite outcomes and was associated with an 
increased risk of stroke (Figure). Findings in the TREAT study 
appear to differ from those of the Correction of Hemoglobin and 
Outcomes in Renal Insufficiency (CHOIR) trial, the next largest 
trial involving patients with chronic kidney disease who were not 
undergoing dialysis, which used epoetin alfa and was discontinued 
prematurely after a median follow-up of 16 months and after 222 
patients had a primary event.1 Both groups in the CHOIR trial 
were randomly assigned to receive epoetin alfa. In that study, there 
was a higher risk of cardiovascular events in the group assigned to 
a target hemoglobin level of 13.5 g/dl than in the group assigned 
to a target level of 11.3 g/dl.
The results of TREAT will influence practice guidelines and 
inform physicians, patients, and policy makers. In many patients, 
the risk of stroke will outweigh the potential benefits of darbepoetin 
alfa. One can anticipate substantive interest in subsequent thoughtful 
analyses of secondary outcomes, especially quality-of-life studies. 
Whether there were differences between the study groups in the rates 
of change in the estimated glomerular filtration rate will be of inter-
est, as will the lower number of cardiovascular revascularizations in 
the darbepoetin alfa group than in the placebo group.2
Marc De Broe
1N Engl J Med 2006; 355: 2085–2098. 2N Engl J Med 2009; 361: 2089–2090.
Comparative effectiveness of 
angiotensin-converting enzyme 
inhibitors and angiotensin II receptor 
blockers for ischemic heart disease
Baker et al., Ann Intern Med 2009; 151: 861–871
One goal of the American Recovery and Reinvestment Act of 2009 
was to emphasize research that judges comparative effectiveness. 
Studies such as a recent one by Baker et al. demonstrate the use of 
existing data to qualitatively compare currently available therapies. 
Given the tremendous probability that patients with kidney disease 
have concurrent heart disease, the conclusions of this study should 
particularly interest nephrologists.
The investigators of this study sought unpublished data for trials 
comparing the benefits and safety of angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin II receptor blockers (ARBs), or 
combination therapy in adults with stable ischemic heart disease and 
preserved ventricular function. 
Seven trials, enrolling a total of 32,559 participants, demonstrated 
that ACE inhibitors reduced the relative risk (RR) for mortality by 
13% and for nonfatal myocardial infarction by 17% compared with 
placebo. Not surprisingly, the RRs for syncope and cough were 
increased. However, only one study was available to examine this 
question using ARBs. In this single study, ARBs reduced the RR 
for cardiovascular mortality, nonfatal myocardial infarction, or 
stroke together but did not demonstrate a benefit for the individual 
compon ents. One trial enrolling 25,620 participants showed simi-
lar effects on total mortality (RR 1.07) and myocardial infarction 
(RR 1.08) with combination therapy compared with ACE inhib-
itors alone. The combination therapy, however, also resulted in an 
increased risk of hypotension and syncope.
The evidence that ACE inhibitors prolong survival and reduce 
cardiovascular events is clearly stronger than the evidence that ARBs 
do so. While the goal of nephrologists is frequently focused on the 
reduction of proteinuria as an intermediate outcome, these results 
suggest that ACE inhibitors be considered first, given the greater 
comparative strength of the evidence in harder clinical outcomes.
Lynda Szczech
Kaplan–Meier estimate of the probability shows the primary 
cardiovascular composite end point.
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